Eboli Paula, Ryan Robert W, Alexander Julia E, Alexander Michael J
Neurol Res. 2014 Apr;36(4):332-8. doi: 10.1179/1743132814Y.0000000324. Epub 2014 Feb 18.
This study evaluates the role of endovascular therapy for middle cerebral artery (MCA) aneurysms and its evolution over time. We are reporting a large case series of 184 MCA aneurysms and comparative analysis of the literature.
This was a retrospective review of a prospectively maintained database including all patients with MCA bifurcation aneurysms embolized between 2000 and 2013. There were 184 aneurysms in 166 patients, with 71 ruptured and 113 nonruptured aneurysms.
Stent assistance was required in 70 cases (38·0%) and 3 cases (1·6%) required 'Y' stenting. The initial rate of total aneurysm occlusion was 59·8% and at delayed follow up was 90·1%. Seven embolizations resulted in thrombo-embolic complications (3·8%), with no cases of aneurysm re-bleeding, wire perforations, or other hemorrhages. Three patients with ruptured aneurysms died of causes unrelated to the embolization, and none with nonruptured aneurysms died in the follow-up period (total mortality 1·6% at 30 days post-procedure). A total of seven aneurysms (3·9%) required retreatment with an average follow up of 41 months. Prior to dedicated aneurysm stents, 68·8% of patients underwent embolization with the remainder surgically treated. Following the introduction of aneurysm stents in 2002, 92·0% of MCA aneurysms treated were embolized.
During the past decade we have seen a treatment paradigm shift in MCA aneurysm treatment from surgical treatment to endovascular treatment. Developments in 3D angiography, more compliant balloons, dedicated aneurysm stents, complex coils, and antiplatelet therapy regimes have led to this transition for safe and effective management of these patients.
本研究评估血管内治疗对大脑中动脉(MCA)动脉瘤的作用及其随时间的演变。我们报告了184例MCA动脉瘤的大型病例系列以及文献的对比分析。
这是一项对前瞻性维护数据库的回顾性研究,纳入了2000年至2013年间所有接受MCA分叉动脉瘤栓塞治疗的患者。166例患者中有184个动脉瘤,其中71个为破裂动脉瘤,113个为未破裂动脉瘤。
70例(38.0%)需要支架辅助,3例(1.6%)需要“Y”形支架置入。动脉瘤完全闭塞的初始率为59.8%,延迟随访时为90.1%。7次栓塞导致血栓栓塞并发症(3.8%),无动脉瘤再出血、导丝穿孔或其他出血病例。3例破裂动脉瘤患者死于与栓塞无关的原因,随访期间未破裂动脉瘤患者无死亡(术后30天总死亡率为1.6%)。共有7个动脉瘤(3.9%)需要再次治疗,平均随访41个月。在专用动脉瘤支架出现之前,68.8%的患者接受了栓塞治疗,其余患者接受了手术治疗。2002年引入动脉瘤支架后,92.0%接受治疗的MCA动脉瘤采用了栓塞治疗。
在过去十年中,我们看到MCA动脉瘤的治疗模式从手术治疗转向了血管内治疗。三维血管造影、更顺应性的球囊、专用动脉瘤支架、复杂线圈和抗血小板治疗方案的发展导致了这种转变,以安全有效地管理这些患者。